The U.S. Food and Drug Administration (FDA) and Customs and Border Protection (CBP) are set to implement new rules in January that will effectively ban nearly all personal imports of prescription medications. This move is expected to impact millions of Americans who rely on Canadian pharmacies to obtain more affordable drugs, potentially leading to significant increases in out-of-pocket costs.

The policy had initially been targeted to take effect on October 22 but was delayed following concerns about raising drug prices just weeks before the midterm elections. Officials from the Trump administration reportedly decided to postpone enforcement to avoid political fallout, though the delay is widely seen as temporary.

Prescription drug prices in the United States are substantially higher than those in other developed countries. A recent survey by the Kaiser Family Foundation showed that 60 percent of American adults are concerned about affording their medications, with nearly half reporting that they have either skipped doses, failed to fill prescriptions, or employed other cost-saving measures.

The new restriction aligns with President Donald Trump’s approach to protecting the domestic pharmaceutical industry, reflecting an emphasis on preserving profits for U.S.-based drug manufacturers. Critics argue that this protectionism unfairly burdens consumers who have sought more affordable options through Canadian pharmacies, which often offer the same medications at a fraction of U.S. prices.

One patient with glaucoma, who has been managing the condition for eight years, highlighted the practical implications of the rule. After trying various prescription eye drops, she found that Lumigan was the only effective medication that did not cause severe side effects. However, Lumigan is significantly more expensive in the United States than in Canada. By purchasing from a licensed Canadian pharmacy online, she has been able to obtain the drug for roughly one-third of the U.S. price, after providing a valid prescription from her Maryland ophthalmologist.

The issue of importing prescription drugs from Canada gained attention during Trump’s 2012 re-election campaign, when he advocated for state governments to purchase medications at lower prices from Canadian sources. Former Secretary of Health and Human Services Alex Azar supported the idea, stating that imports from Canada posed no added public health risk and could lead to substantial reductions in drug costs for American consumers. However, the proposal ultimately failed to gain traction, facing opposition from U.S. pharmaceutical manufacturers concerned about protecting their market share.

For many patients under 65, drug pricing is mitigated by insurance benefits, discounts, and rebates. Yet, the new import restrictions could limit access to more affordable alternatives, particularly for those who do not qualify for Medicare or other government programs.

As the January enforcement date approaches, stakeholders on both sides of the issue continue to debate the balance between drug affordability for consumers and protecting the domestic pharmaceutical industry’s interests.